Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: Practical considerations from published data

Journal of the American College of Cardiology

Volumn 63, Issue 9, 2014, Pages 853-871

  Damman, Kevin ^a,b   Tang, W H Wilson ^c   Felker, G Michael ^d   Lassus, Johan ^e   Zannad, Faiez ^f   Krum, Henry ^g   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c LERNER RESEARCH INSTITUTE   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^f UNIVERSITÉ DE LORRAINE   (France)

^g MONASH UNIVERSITY   (Australia)

Author keywords

evidence based treatment; heart failure; pharmacological treatment; renal insufficiency

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; IVABRADINE; MINERALOCORTICOID ANTAGONIST; BISOPROLOL; CANDESARTAN; CAPTOPRIL; CARVEDILOL; DIGITALIS; ENALAPRIL; EPLERENONE; LISINOPRIL; LOSARTAN; METOPROLOL; NEBIVOLOL; PLACEBO; PRAZOSIN; RAMIPRIL; SPIRONOLACTONE; TORASEMIDE; TRANDOLAPRIL; VALSARTAN;

ADD ON THERAPY; ALBUMINURIA; CARDIAC RESYNCHRONIZATION THERAPY; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL PRACTICE; DEFIBRILLATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EXCRETION; EVIDENCE BASED MEDICINE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; OUTCOME ASSESSMENT; PATIENT SAFETY; PERSONALIZED MEDICINE; PHARMACOLOGICAL BLOCKING; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTOLIC HEART FAILURE; ARTICLE; CARDIOVASCULAR MORTALITY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; HEART DEATH; HEART INFARCTION; HOSPITALIZATION; KIDNEY FAILURE; KIDNEY FUNCTION; LOADING DRUG DOSE; LOW DRUG DOSE; META ANALYSIS (TOPIC); OPTIMAL DRUG DOSE; SIDE EFFECT;

EVIDENCE-BASED TREATMENT; HEART FAILURE; PHARMACOLOGICAL TREATMENT; RENAL INSUFFICIENCY;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIAC RESYNCHRONIZATION THERAPY; ELECTROLYTES; EVIDENCE-BASED MEDICINE; GLOMERULAR FILTRATION RATE; HEART FAILURE, SYSTOLIC; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY; RENIN-ANGIOTENSIN SYSTEM; RISK; TREATMENT OUTCOME;

EID: 84895537143     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.11.031     Document Type: Review

References (81)

1. J.J. McMurray, S. Adamopoulos, and S.D. Anker et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC Eur J Heart Fail 14 2012 803 869
2. C.W. Yancy, M. Jessup, and B. Bozkurt et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 62 2013 e147 e239
3. J.T. Heywood, G.C. Fonarow, and C.W. Yancy et al. Influence of renal function on the use of guideline-recommended therapies for patients with heart failure Am J Cardiol 105 2010 1140 1146
4. N. Hawwa, M.J. Schreiber Jr., and W.H. Tang Pharmacologic management of chronic reno-cardiac syndrome Curr Heart Fail Rep 10 2013 54 62
5. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2002 S1 S266
6. F.A. McAlister, J. Ezekowitz, and L. Tarantini et al. Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula Circ Heart Fail 5 2012 309 314
7. F. Zannad, J.J. McMurray, and H. Krum et al. Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 2011 11 21
8. L. Tavazzi, A.P. Maggioni, and R. Marchioli et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1231 1239
9. J. Kjekshus, E. Apetrei, and V. Barrios et al. Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2007 2248 2261
10. M.D. Flather, M.C. Shibata, and A.J. Coats et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur Heart J 26 2005 215 225
11. B. Waldum, A.S. Westheim, and L. Sandvik et al. Renal function in outpatients with chronic heart failure J Card Fail 16 2010 374 380
12. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
13. C.E. Jackson, S.D. Solomon, and H.C. Gerstein et al. Albuminuria in chronic heart failure: prevalence and prognostic importance Lancet 374 2009 543 550
14. S. Masson, R. Latini, and V. Milani et al. Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial Circ Heart Fail 3 2010 65 72
15. C. Ronco, M. Haapio, A.A. House, N. Anavekar, and R. Bellomo Cardiorenal syndrome J Am Coll Cardiol 52 2008 1527 1539
16. K. Swedberg, P. Eneroth, J. Kjekshus, and S. Snapinn Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group Am J Cardiol 66 1990 40D 44D
17. J. Kjekshus, and K. Swedberg Enalapril for congestive heart failure Am J Cardiol 63 1989 26D 32D
18. C.B. Bowling, P.W. Sanders, and R.M. Allman et al. Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial Int J Cardiol 167 2012 151 156
19. B.M. Massie, P.W. Armstrong, and J.G. Cleland et al. Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival Arch Intern Med 161 2001 165 171
20. M.P. Tokmakova, H. Skali, and S. Kenchaiah et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study Circulation 110 2004 3667 3673
21. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 316 1987 1429 1435
22. M.A. Konstam, J.D. Neaton, and K. Dickstein et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial Lancet 374 2009 1840 1848
23. B. Pitt, R. Segal, and F.A. Martinez et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) Lancet 349 1997 747 752
24. B. Pitt, P.A. Poole-Wilson, and R. Segal et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II Lancet 355 2000 1582 1587
25. K. Dickstein, and J. Kjekshus Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Lancet 360 2002 752 760
26. M.A. Pfeffer, J.J. McMurray, and E.J. Velazquez et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906
27. I.S. Anand, K. Bishu, T.S. Rector, A. Ishani, M.A. Kuskowski, and J.N. Cohn Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure Circulation 120 2009 1577 1584
28. A.S. Desai, K. Swedberg, and J.J. McMurray et al. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program J Am Coll Cardiol 50 2007 1959 1966
29. J.F. Mann, R.E. Schmieder, and M. McQueen et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial Lancet 372 2008 547 553
30. G. Cice, A. Di Benedetto, and S. D'Isa et al. Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial J Am Coll Cardiol 56 2010 1701 1708
31. B. Pitt, F. Zannad, W.J. Remme for the Randomized Aldactone Evaluation Study Investigators The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 1999 709 717
32. O. Vardeny, D.H. Wu, and A. Desai et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study) J Am Coll Cardiol 60 2012 2082 2089
33. B. Pitt, W. Remme, and F. Zannad et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
34. J.K. Ghali, J. Wikstrand, and D.J. van Veldhuisen et al. The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR/XL Randomized Intervention Trial in Chronic HF (MERIT-HF) J Card Fail 15 2009 310 318
35. D. Castagno, P.S. Jhund, and J.J. McMurray et al. Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial Eur J Heart Fail 12 2010 607 616
36. A. Cohen-Solal, D. Kotecha, and D.J. van Veldhuisen et al. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial Eur J Heart Fail 11 2009 872 880
37. R.K. Wali, M. Iyengar, and G.J. Beck et al. Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials Circ Heart Fail 4 2011 18 26
38. G. Cice, L. Ferrara, and A. D'Andrea et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial J Am Coll Cardiol 41 2003 1438 1444
39. DIG investigators The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group N Engl J Med 336 1997 525 533
40. M.G. Shlipak, G.L. Smith, S.S. Rathore, B.M. Massie, and H.M. Krumholz Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial J Am Soc Nephrol 15 2004 2195 2203
41. K. Swedberg, M. Komajda, and M. Bohm et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study Lancet 376 2010 875 885
42. K. Fox, I. Ford, P.G. Steg, M. Tendera, and R. Ferrari Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 807 816
43. J.N. Cohn, D.G. Archibald, and S. Ziesche et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study N Engl J Med 314 1986 1547 1552
44. A.L. Taylor, S. Ziesche, and C.W. Yancy et al. Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial Circulation 115 2007 1747 1753
45. K. Damman, M.J. Ng Kam Chuen, and R.J. MacFadyen et al. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function J Am Coll Cardiol 57 2011 2233 2241
46. M.D. Murray, M.M. Deer, and J.A. Ferguson et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure Am J Med 111 2001 513 520
47. B. Bikdeli, K.M. Strait, and K. Dharmarajan et al. Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives? J Am Coll Cardiol 61 2013 1549 1550
48. J. Cosin, and J. Diez Torasemide in chronic heart failure: results of the TORIC study Eur J Heart Fail 4 2002 507 513
49. G.H. Bardy, K.L. Lee, and D.B. Mark et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med 352 2005 225 237
50. A.J. Moss, W.J. Hall, D.S. Cannom for the Multicenter Automatic Defibrillator Implantation Trial Investigators Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia N Engl J Med 335 1996 1933 1940
51. A. Kadish, A. Dyer, and J.P. Daubert et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy N Engl J Med 350 2004 2151 2158
52. A.J. Moss, W. Zareba, and W.J. Hall et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction N Engl J Med 346 2002 877 883
53. The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias N Engl J Med 337 1997 1576 1583
54. D. Bansch, M. Antz, and S. Boczor et al. Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT) Circulation 105 2002 1453 1458
55. S.J. Connolly, M. Gent, and R.S. Roberts et al. Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone Circulation 101 2000 1297 1302
56. K.H. Kuck, R. Cappato, J. Siebels, and R. Ruppel Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH) Circulation 102 2000 748 754
57. I. Goldenberg, A.J. Moss, and S. McNitt et al. Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction Am J Cardiol 98 2006 485 490
58. J.G. Cleland, J.C. Daubert, and E. Erdmann et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure N Engl J Med 352 2005 1539 1549
59. A.J. Moss, W.J. Hall, and D.S. Cannom et al. Cardiac-resynchronization therapy for the prevention of heart-failure events N Engl J Med 361 2009 1329 1338
60. I. Goldenberg, A.J. Moss, and S. McNitt et al. Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial - Cardiac Resynchronization Therapy (MADIT-CRT) Heart Rhythm 7 2010 1777 1782
61. A.S. Tang, G.A. Wells, and M. Talajic et al. Cardiac-resynchronization therapy for mild-to-moderate heart failure N Engl J Med 363 2010 2385 2395
62. G. Boerrigter, L.C. Costello-Boerrigter, and W.T. Abraham et al. Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate J Card Fail 14 2008 539 546
63. N. Garg, G. Thomas, and G. Jackson et al. Cardiac resynchronization therapy in CKD: a systematic review Clin J Am Soc Nephrol 8 2013 1293 1303
64. W.T. Abraham, W.G. Fisher, and A.L. Smith et al. Cardiac resynchronization in chronic heart failure N Engl J Med 346 2002 1845 1853
65. H.L. Hillege, W.H. van Gilst, and D.J. van Veldhuisen et al. Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial Eur Heart J 24 2003 412 420
66. J.M. Testani, S.E. Kimmel, D.L. Dries, and S.G. Coca Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction Circ Heart Fail 4 2011 685 691
67. P. Rossignol, J.G. Cleland, and S. Bhandari et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Circulation 125 2012 271 279
68. S. Ljungman, J. Kjekshus, and K. Swedberg Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial) Am J Cardiol 70 1992 479 487
69. K. Damman, G. Navis, and A.A. Voors et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis J Card Fail 13 2007 599 608
70. M.G. Shlipak Pharmacotherapy for heart failure in patients with renal insufficiency Ann Intern Med 138 2003 917 924
71. C.B. Granger, J.J. McMurray, and S. Yusuf et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776
72. S. Yusuf, M.A. Pfeffer, and K. Swedberg et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial Lancet 362 2003 777 781
73. The NETWORK Investigators Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison Eur Heart J 19 1998 481 489
74. E.L. Knight, R.J. Glynn, K.M. McIntyre, H. Mogun, and J. Avorn Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD) Am Heart J 138 1999 849 855
75. M. Metra, S. Nodari, and G. Parrinello et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance Eur J Heart Fail 10 2008 188 195
76. R. Eschalier, J.J. McMurray, and K. Swedberg et al. Safety and efficacy of eplerenone in patients at high-risk for hyperkalemia and/or worsening renal function: analyses of EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) J Am Coll Cardiol 62 2013 1585 1593
77. T. Kumler, G.H. Gislason, L. Kober, F. Gustafsson, M. Schou, and C. Torp-Pedersen Renal function at the time of a myocardial infarction maintains prognostic value for more than 10 years BMC Cardiovasc Disord 11 2011 37
78. H.L. Hillege, D. Nitsch, and M.A. Pfeffer et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure Circulation 113 2006 671 678
79. C. Leclercq, S. Walker, and C. Linde et al. Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation Eur Heart J 23 2002 1780 1787
80. J.B. Young, W.T. Abraham, and A.L. Smith et al. Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial JAMA 289 2003 2685 2694
81. J.H. Youn, J. Lord, K. Hemming, A. Girling, and M. Buxton Bayesian meta-analysis on medical devices: application to implantable cardioverter defibrillators Int J Technol Assess Health Care 28 2012 115 124